Security record · archived quarter
VNDA
Vanda Pharmaceuticals Inc. · Healthcare · Biotechnology
11Tracked holders
—Δ holders
6.99MShares held
$39.47MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | 0 | 37.76M | $231.07M | +7 | −7 |
| Q1 2026 | 78 | +6 | 33.85M | $233.91M | +14 | −8 |
| Q4 2025 | 72 | -1 | 30.64M | $270.14M | +1 | −2 |
| Q3 2025 | 17 | 0 | 25.97M | $129.59M | — | −1 |
| Q2 2025 | 15 | 0 | 24.58M | $116.00M | — | — |
| Q1 2025 | 12 | 0 | 9.69M | $44.48M | — | — |
| Q4 2024 | 12 | +1 | 8.66M | $41.48M | +1 | — |
| Q3 2024 | 10 | -1 | 7.15M | $33.54M | — | −1 |
| Q2 2024 | 11 | — | 6.99M | $39.47M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 4.11M | — | $23.24M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.33M | — | $7.52M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.33M | — | $7.52M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 692.74K | — | $3.91M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 692.74K | — | $3.91M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 365.76K | — | $2.07M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 365.76K | — | $2.07M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 147.44K | — | $833,013 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 115.00K | — | $649,750 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 85.77K | — | $484,595 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 75.89K | — | $428,772 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 75.89K | — | $428,772 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 75.89K | — | $428,772 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 24.50K | — | $138,448 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 17.03K | — | $97,000 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 16.24K | — | $91,739 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 168 holders, 45.91M shares, $293.46M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API